U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Defective DNA repair after ultraviolet radiation damage

MedGen UID:
368469
Concept ID:
C1968564
Finding
HPO: HP:0003079

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVDefective DNA repair after ultraviolet radiation damage

Conditions with this feature

DE SANCTIS-CACCHIONE SYNDROME
MedGen UID:
75550
Concept ID:
C0265201
Disease or Syndrome
A rare autosomal recessive inherited syndrome. It is characterized by xeroderma pigmentosum, mental retardation, dwarfism, hypogonadism, and neurologic abnormalities.
Xeroderma pigmentosum group A
MedGen UID:
82775
Concept ID:
C0268135
Disease or Syndrome
Xeroderma pigmentosum (XP) is characterized by: Acute sun sensitivity (severe sunburn with blistering, persistent erythema on minimal sun exposure) with marked freckle-like pigmentation of the face before age two years; Sunlight-induced ocular involvement (photophobia, severe keratitis, atrophy of the skin of the lids, ocular surface neoplasms); Greatly increased risk of sunlight-induced cutaneous neoplasms (basal cell carcinoma, squamous cell carcinoma, melanoma) within the first decade of life. Approximately 25% of affected individuals have neurologic manifestations (acquired microcephaly, diminished or absent deep tendon stretch reflexes, progressive sensorineural hearing loss, progressive cognitive impairment, and ataxia). The most common causes of death are skin cancer, neurologic degeneration, and internal cancer. The median age at death in persons with XP with neurodegeneration (29 years) was found to be younger than that in persons with XP without neurodegeneration (37 years).
Xeroderma pigmentosum, group D
MedGen UID:
75656
Concept ID:
C0268138
Disease or Syndrome
Xeroderma pigmentosum (XP) is characterized by: Acute sun sensitivity (severe sunburn with blistering, persistent erythema on minimal sun exposure) with marked freckle-like pigmentation of the face before age two years; Sunlight-induced ocular involvement (photophobia, severe keratitis, atrophy of the skin of the lids, ocular surface neoplasms); Greatly increased risk of sunlight-induced cutaneous neoplasms (basal cell carcinoma, squamous cell carcinoma, melanoma) within the first decade of life. Approximately 25% of affected individuals have neurologic manifestations (acquired microcephaly, diminished or absent deep tendon stretch reflexes, progressive sensorineural hearing loss, progressive cognitive impairment, and ataxia). The most common causes of death are skin cancer, neurologic degeneration, and internal cancer. The median age at death in persons with XP with neurodegeneration (29 years) was found to be younger than that in persons with XP without neurodegeneration (37 years).
Xeroderma pigmentosum, group F
MedGen UID:
120612
Concept ID:
C0268140
Congenital Abnormality
Xeroderma pigmentosum (XP) is characterized by: Acute sun sensitivity (severe sunburn with blistering, persistent erythema on minimal sun exposure) with marked freckle-like pigmentation of the face before age two years; Sunlight-induced ocular involvement (photophobia, severe keratitis, atrophy of the skin of the lids, ocular surface neoplasms); Greatly increased risk of sunlight-induced cutaneous neoplasms (basal cell carcinoma, squamous cell carcinoma, melanoma) within the first decade of life. Approximately 25% of affected individuals have neurologic manifestations (acquired microcephaly, diminished or absent deep tendon stretch reflexes, progressive sensorineural hearing loss, progressive cognitive impairment, and ataxia). The most common causes of death are skin cancer, neurologic degeneration, and internal cancer. The median age at death in persons with XP with neurodegeneration (29 years) was found to be younger than that in persons with XP without neurodegeneration (37 years).
Xeroderma pigmentosum, group G
MedGen UID:
75657
Concept ID:
C0268141
Disease or Syndrome
Xeroderma pigmentosum (XP) is characterized by: Acute sun sensitivity (severe sunburn with blistering, persistent erythema on minimal sun exposure) with marked freckle-like pigmentation of the face before age two years; Sunlight-induced ocular involvement (photophobia, severe keratitis, atrophy of the skin of the lids, ocular surface neoplasms); Greatly increased risk of sunlight-induced cutaneous neoplasms (basal cell carcinoma, squamous cell carcinoma, melanoma) within the first decade of life. Approximately 25% of affected individuals have neurologic manifestations (acquired microcephaly, diminished or absent deep tendon stretch reflexes, progressive sensorineural hearing loss, progressive cognitive impairment, and ataxia). The most common causes of death are skin cancer, neurologic degeneration, and internal cancer. The median age at death in persons with XP with neurodegeneration (29 years) was found to be younger than that in persons with XP without neurodegeneration (37 years).
Xeroderma pigmentosum, group E
MedGen UID:
341219
Concept ID:
C1848411
Congenital Abnormality
Xeroderma pigmentosum (XP) is characterized by: Acute sun sensitivity (severe sunburn with blistering, persistent erythema on minimal sun exposure) with marked freckle-like pigmentation of the face before age two years; Sunlight-induced ocular involvement (photophobia, severe keratitis, atrophy of the skin of the lids, ocular surface neoplasms); Greatly increased risk of sunlight-induced cutaneous neoplasms (basal cell carcinoma, squamous cell carcinoma, melanoma) within the first decade of life. Approximately 25% of affected individuals have neurologic manifestations (acquired microcephaly, diminished or absent deep tendon stretch reflexes, progressive sensorineural hearing loss, progressive cognitive impairment, and ataxia). The most common causes of death are skin cancer, neurologic degeneration, and internal cancer. The median age at death in persons with XP with neurodegeneration (29 years) was found to be younger than that in persons with XP without neurodegeneration (37 years).
XFE progeroid syndrome
MedGen UID:
410064
Concept ID:
C1970416
Disease or Syndrome
An autosomal recessive condition caused by mutation(s) in the ERCC4 gene, encoding DNA repair endonuclease XPF. it is characterized by characterized by cutaneous photosensitivity and progeroid features in multiple organ systems.
Xeroderma pigmentosum, group C
MedGen UID:
416702
Concept ID:
C2752147
Disease or Syndrome
Xeroderma pigmentosum (XP) is characterized by: Acute sun sensitivity (severe sunburn with blistering, persistent erythema on minimal sun exposure) with marked freckle-like pigmentation of the face before age two years; Sunlight-induced ocular involvement (photophobia, severe keratitis, atrophy of the skin of the lids, ocular surface neoplasms); Greatly increased risk of sunlight-induced cutaneous neoplasms (basal cell carcinoma, squamous cell carcinoma, melanoma) within the first decade of life. Approximately 25% of affected individuals have neurologic manifestations (acquired microcephaly, diminished or absent deep tendon stretch reflexes, progressive sensorineural hearing loss, progressive cognitive impairment, and ataxia). The most common causes of death are skin cancer, neurologic degeneration, and internal cancer. The median age at death in persons with XP with neurodegeneration (29 years) was found to be younger than that in persons with XP without neurodegeneration (37 years).

Professional guidelines

PubMed

Alapetite C, Benoit A, Moustacchi E, Sarasin A
J Invest Dermatol 1997 Feb;108(2):154-9. doi: 10.1111/1523-1747.ep12332692. PMID: 9008227

Recent clinical studies

Etiology

Costa MI, Lapa BS, Jorge J, Alves R, Carreira IM, Sarmento-Ribeiro AB, Gonçalves AC
Int J Mol Sci 2022 Feb 25;23(5) doi: 10.3390/ijms23052567. PMID: 35269710Free PMC Article
Morifuji M
Exp Dermatol 2019 Feb;28 Suppl 1:28-31. doi: 10.1111/exd.13825. PMID: 30698876
Shah P, Zhao B, Qiang L, He YY
Nucleic Acids Res 2018 Jun 1;46(10):5050-5060. doi: 10.1093/nar/gky239. PMID: 29660033Free PMC Article
Sugasawa K
DNA Repair (Amst) 2016 Aug;44:110-117. Epub 2016 May 20 doi: 10.1016/j.dnarep.2016.05.015. PMID: 27264556
Moriwaki S
J Dermatol Sci 2016 Feb;81(2):77-84. Epub 2015 Oct 1 doi: 10.1016/j.jdermsci.2015.09.008. PMID: 26493104

Diagnosis

Calses PC, Dhillon KK, Tucker N, Chi Y, Huang JW, Kawasumi M, Nghiem P, Wang Y, Clurman BE, Jacquemont C, Gafken PR, Sugasawa K, Saijo M, Taniguchi T
Cell Rep 2017 Apr 4;19(1):162-174. doi: 10.1016/j.celrep.2017.03.021. PMID: 28380355Free PMC Article
Xiang Y, Laurent B, Hsu CH, Nachtergaele S, Lu Z, Sheng W, Xu C, Chen H, Ouyang J, Wang S, Ling D, Hsu PH, Zou L, Jambhekar A, He C, Shi Y
Nature 2017 Mar 23;543(7646):573-576. Epub 2017 Mar 15 doi: 10.1038/nature21671. PMID: 28297716Free PMC Article
Moriwaki S
J Dermatol Sci 2016 Feb;81(2):77-84. Epub 2015 Oct 1 doi: 10.1016/j.jdermsci.2015.09.008. PMID: 26493104
Uittenboogaard LM, Payan-Gomez C, Pothof J, van Ijcken W, Mastroberardino PG, van der Pluijm I, Hoeijmakers JH, Tresini M
DNA Repair (Amst) 2013 Nov;12(11):982-92. Epub 2013 Sep 24 doi: 10.1016/j.dnarep.2013.08.016. PMID: 24075570Free PMC Article
Kaufmann WK
Cancer Metastasis Rev 1995 Mar;14(1):31-41. doi: 10.1007/BF00690209. PMID: 7606819

Therapy

Fukuda T, Komaki Y, Mori Y, Ibuki Y
Mutat Res Genet Toxicol Environ Mutagen 2021 Jul;867:503374. Epub 2021 Jun 18 doi: 10.1016/j.mrgentox.2021.503374. PMID: 34266626
Morifuji M
Exp Dermatol 2019 Feb;28 Suppl 1:28-31. doi: 10.1111/exd.13825. PMID: 30698876
Moriwaki S
J Dermatol Sci 2016 Feb;81(2):77-84. Epub 2015 Oct 1 doi: 10.1016/j.jdermsci.2015.09.008. PMID: 26493104
Sertic S, Pizzi S, Lazzaro F, Plevani P, Muzi-Falconi M
Cell Cycle 2012 Feb 15;11(4):668-74. doi: 10.4161/cc.11.4.19117. PMID: 22373527
Ananthaswamy HN, Pierceall WE
Photochem Photobiol 1990 Dec;52(6):1119-36. doi: 10.1111/j.1751-1097.1990.tb08452.x. PMID: 2087500

Prognosis

Shah P, Zhao B, Qiang L, He YY
Nucleic Acids Res 2018 Jun 1;46(10):5050-5060. doi: 10.1093/nar/gky239. PMID: 29660033Free PMC Article
Zhang X, Horibata K, Saijo M, Ishigami C, Ukai A, Kanno S, Tahara H, Neilan EG, Honma M, Nohmi T, Yasui A, Tanaka K
Nat Genet 2012 May;44(5):593-7. doi: 10.1038/ng.2228. PMID: 22466612
Schaffer JV, Orlow SJ
Dermatology 2011;223(2):97-103. Epub 2011 Oct 21 doi: 10.1159/000324509. PMID: 22024645
Alapetite C, Benoit A, Moustacchi E, Sarasin A
J Invest Dermatol 1997 Feb;108(2):154-9. doi: 10.1111/1523-1747.ep12332692. PMID: 9008227
Giannelli F, Botcherby PK, Marimo B, Magnus IA
Lancet 1983 Jan 15;1(8316):88-91. doi: 10.1016/s0140-6736(83)91740-3. PMID: 6184584

Clinical prediction guides

Bigagli E, Cinci L, D'Ambrosio M, Nardini P, Portelli F, Colucci R, Lodovici M, Mugelli A, Luceri C
Oxid Med Cell Longev 2021;2021:6655542. Epub 2021 Aug 14 doi: 10.1155/2021/6655542. PMID: 34434485Free PMC Article
Shah P, Zhao B, Qiang L, He YY
Nucleic Acids Res 2018 Jun 1;46(10):5050-5060. doi: 10.1093/nar/gky239. PMID: 29660033Free PMC Article
Berra CM, de Oliveira CS, Garcia CC, Rocha CR, Lerner LK, Lima LC, Baptista Mda S, Menck CF
Free Radic Biol Med 2013 Aug;61:343-56. Epub 2013 Apr 6 doi: 10.1016/j.freeradbiomed.2013.03.026. PMID: 23567189
Kaufmann WK
Cancer Metastasis Rev 1995 Mar;14(1):31-41. doi: 10.1007/BF00690209. PMID: 7606819
Regan JD, Setlow RB, Ley RD
Proc Natl Acad Sci U S A 1971 Apr;68(4):708-12. doi: 10.1073/pnas.68.4.708. PMID: 5279512Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...